Oncology Biosimilar Market Size, Share, Growth Report 2030

Oncology Biosimilar Market

Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2024

Published Date: 12-Jul-2018 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-3228 Status : Published

The study provides a decisive view on the oncology biosimilar market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024. 

The report covers forecast and analysis for the oncology biosimilar market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based revenue (USD Million). The study includes drivers and restraints for the oncology biosimilar market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the oncology biosimilar market on a global level.

In order to give the users of this report a comprehensive view on the oncology biosimilar market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, where test type, drug type, distribution channel and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

Global Oncology Biosimilar MarketRequest Free Sample

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new test type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis.

The study provides a decisive view on the oncology biosimilar market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2018 to 2024. 

Based on test type, the oncology biosimilar market is segmented as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer and others. Based on the distribution channel, the oncology biosimilar market is segmented as retail pharmacies, hospital pharmacy, and online pharmacy. 

Increasing demand for affordable therapies due to the constant increase in cancer patients is one of the major driving factors of oncology biosimilar market. High medical expenses associated with cancer treatment; the lack of awareness and dearth of skilled personnel are factors that influence the market growth during the forecast period.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries, including the U.S., Canada, Mexico, Germany, Spain, Italy, France, UK, China, Japan, India, and Brazil. This segment includes demand for oncology biosimilar market based on individual segment and test types in all the regions and countries.

The report also includes detailed profiles of end players such as Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others. 

This report segments the global oncology biosimilar market as follows:

Global Oncology Biosimilar Market: by Test Type

  • Breast Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Neutropenia Cancer
  • Non-Small Cell Lung Cancer
  • Others

Global Oncology Biosimilar Market: Drug Type Segment Analysis:

  • mAb
  • Immunomodulators
  • Hematopoietic Agents
  • G-CSF 
  • Others

Global Oncology Biosimilar Market: by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacy
  • Online Pharmacy

Global Oncology Biosimilar Market: by Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

Methodology

Free Analysis

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed